Volume 22 Issue 2
Feb.  2024
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2024  >  22(2): 247-251
ZHANG Fen, ZHU Caixia, LIU Yufeng, XIA Yuhan, ZHANG Kedong. Retrospective analysis of risk factors for stable chronic obstructive pulmonary disease combined with pulmonary hypertension[J]. Chinese Journal of General Practice, 2024, 22(2): 247-251. doi: 10.16766/j.cnki.issn.1674-4152.003376
Citation: ZHANG Fen, ZHU Caixia, LIU Yufeng, XIA Yuhan, ZHANG Kedong. Retrospective analysis of risk factors for stable chronic obstructive pulmonary disease combined with pulmonary hypertension[J]. Chinese Journal of General Practice, 2024, 22(2): 247-251. doi: 10.16766/j.cnki.issn.1674-4152.003376
shu

Retrospective analysis of risk factors for stable chronic obstructive pulmonary disease combined with pulmonary hypertension

doi: 10.16766/j.cnki.issn.1674-4152.003376
  • 1.

    Department of Pulmonary and Critical Care Medicine, General Hospital of Ningxia Medical University, Yinchuan, Ningxia 750004, China

Funds:

 2021BEG02027

  • Received Date: 2023-07-30
    Available Online: 2024-03-27
    Abstract
  •   Objective  To analyze the clinical characteristics and risk factors of patients with stable chronic obstructive pulmonary disease (COPD) combined with pulmonary hypertension (PH).  Methods  A total of 199 patients with stable COPD combined with PH and 150 patients with pure stable COPD were collected from January 2020 to January 2022 at General Hospital of Ningxia Medical University as the control group. The clinical data of the two groups were compared, and the clinical characteristics and risk factors of stable COPD combined with different severity of PH were analyzed.  Results  (1) There were significant differences in several clinical indicators between the COPD group and the COPD combined with PH group. Furthermore, the COPD combined with PH patients were further divided into mild, moderate, and severe PH groups, and there were significant differences in red cell volume distribution width (RDW), N-terminal pro-brain natriuretic peptide (NT-proBNP), PCO2, HCO3-, stroke volume (SV), and right ventricular anterior-posterior diameter (RVD) among the three groups (P < 0.05). (2) Correlation analysis showed that cardiac index (CI), systemic immune-inflammation index (SII), and SV were negatively correlated with pulmonary artery pressure, while RDW, PCO2, HCO3-, and NT-proBNP were positively correlated with pulmonary artery pressure. (3) The results of multivariate logistic regression analysis showed that an elevated NT-proBNP level was an independent risk factor for severe PH in stable COPD (P < 0.05). (4) The ROC curve results showed that the AUC value of NT-proBNP was 0.827, higher than the AUC values of RDW and HCO3-.  Conclusion  An elevated NT-proBNP level is an independent risk factor for severe PH in stable COPD. In addition, there is a correlation between CI, SII, RDW, PCO2, HCO3-, NT-proBNP, SV, and RVD in stable COPD combined with PH.

     

    • FullText(HTML)
  • loading
    • References(21)
  • [1]
    Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2021 REPORT)[EB/OL]. (2021-11-18)[2023-05-12]. https://goldcopd.org/goldreports/.
    [2]
    中华医学会呼吸病学分会肺栓塞与肺血管病学组, 中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会, 全国肺栓塞与肺血管病防治协作组, 等. 中国肺动脉高压诊断与治疗指南(2021版)[J]. 中华医学杂志, 2021, 101(1): 11-51. https://www.cnki.com.cn/Article/CJFDTOTAL-QKYX202303020.htm

    Pulmonary Embolism and Pulmonary Vascular Disease Group of the Respiratory Disease Branch of the Chinese Medical Association, Pulmonary Embolism and Pulmonary Vascular Disease Working Committee of the Respiratory Physicians 'Branch of the Chinese Physicians' Association, and National Collaborative Group for the Prevention and Treatment of Pulmonary Embolism and Pulmonary Vascular Disease, et al. Chinese guidelines for the diagnosis and treatment of pulmonary hypertension (2021 edition)[J]. National Medical Journal of China, 2021, 101(1): 11-51. https://www.cnki.com.cn/Article/CJFDTOTAL-QKYX202303020.htm
    [3]
    ZHONG Y, YU P B. Decoding the link between inflammation and pulmonary arterial hypertension[J]. Circulation, 2022, 146(13): 1023-1025. doi: 10.1161/CIRCULATIONAHA.122.059949
    [4]
    HUMBERT M, KOVACS G, HOEPER M M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension[J]. Eur Heart J, 2022, 43(38): 3618-3731. doi: 10.1093/eurheartj/ehac237
    [5]
    KADER M N, MOIZ J A, BHATI P, et al. Diagnostic validity of cardiopulmonary exercise testing for screening pulmonary hypertension in patients with chronic obstructive pulmonary disease[J]. J Cardiopulm Rehabil Prev, 2020, 40(3): 189-194. doi: 10.1097/HCR.0000000000000456
    [6]
    JIANG T T, WANG Q, ZHANG Z P, et al. Value of the neutrophil-to-lymphocyte ratio in chronic obstructive pulmonary disease complicated with pulmonary hypertension[J]. J Int Med Res, 2023, 51(9): 3000605231200266. DOI: 10.1177/03000605231200266.
    [7]
    WANG C, XU J Y, YANG L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health[CPH] study): a national cross-sectional study[J]. Lancet, 2018, 391(10131): 1706-1717. doi: 10.1016/S0140-6736(18)30841-9
    [8]
    NATHAN S D, BARBERA J A, GAINE S P, et al. Pulmonary hypertension in chronic lung disease and hypoxia[J]. Eur Respir J, 2019, 53(1): 1801914. DOI: 10.1183/13993003.01914-2018.
    [9]
    GREDIC M, BLANCO I, KOVACS G, et al. Pulmonary hypertension in chronic obstructive pulmonary disease[J]. Br J Pharmacol, 2021, 178(1): 132-151. doi: 10.1111/bph.14979
    [10]
    VERGARO G, AIMO A, JANUZZI J L, et al. Cardiac biomarkers retain prognostic significance in patients with heart failure and chronic obstructive pulmonary disease[J]. J Cardiovasc Med (Hagerstown), 2022, 23(1): 28-36. doi: 10.2459/JCM.0000000000001281
    [11]
    ERMINI L, SEDDONE S, POLICASTRO P, et al. The cardiac caval index: improving noninvasive assessment of cardiac preload[J]. J Ultrasound Med, 2022, 41(9): 2247-2258. doi: 10.1002/jum.15909
    [12]
    魏瑞奇, 朴春梅, 张文美, 等. 血小板在肺动脉高压发生、发展中的作用[J]. 国际呼吸杂志, 2020, 40(10): 790-795.

    WEI R Q, PU C M, ZHANG W M, et al. The role of platelets in the development and progression of pulmonary hypertension[J]. International Respiratory Journal, 2020, 40(10): 790-795.
    [13]
    KAZIMIERCZYK R, KAMIŃSKI K. The role of platelets in the development and progression of pulmonary arterial hypertension[J]. Adv Med Sci, 2018, 63(2): 312-316. doi: 10.1016/j.advms.2018.04.013
    [14]
    GALLARDO-VARA E, NTOKOU A, DAVE J M, et al. Vascular pathobiology of pulmonary hypertension[J]. J Heart Lung Transplant, 2023, 42(5): 544-552. doi: 10.1016/j.healun.2022.12.012
    [15]
    ZHU Y, SHU D, GONG X, et al. Platelet-Derived TGF (Transforming Growth Factor)-β1 enhances the aerobic glycolysis of pulmonary arterial smooth muscle cells by PKM2 (Pyruvate Kinase Muscle Isoform 2) upregulation[J]. Hypertension, 2022, 79(5): 932-945. doi: 10.1161/HYPERTENSIONAHA.121.18684
    [16]
    BALTAZARES-LIPP M E, AGUILERA-VELASCO A, AQUINO-GÁLVEZ A, et al. Evaluating of red blood cell distribution width, comorbidities and electrocardiographic ratios as predictors of prognosis in patients with pulmonary hypertension[J]. Diagnostics (Basel), 2021, 11(7): 1297. doi: 10.3390/diagnostics11071297
    [17]
    VITKAUSKAITE A, URBONIENE D, CELIESIUTE J, et al. Circulating inflammatory markers in cervical cancer patients and healthy controls[J]. J Immunotoxicol, 2020, 17(1): 105-109. doi: 10.1080/1547691X.2020.1755397
    [18]
    朱悦, 孙耕耘. 中性粒细胞/淋巴细胞比值及血小板相关指标与OSAS患者严重程度的相关性研究[J]. 中华全科医学, 2019, 17(3): 347-350, 474. doi: 10.16766/j.cnki.issn.1674-4152.000678

    ZHU Y, SUN G Y. NLR, PLR and MPV related to the severity of obstructive sleep apnea syndrome[J]. Chinese Journal of General Practice, 2019, 17(3): 347-350, 474. doi: 10.16766/j.cnki.issn.1674-4152.000678
    [19]
    SHAHMORADI Z, MALEKMOHAMMAD M, NAJAFI G, et al. Prognostic value of platelet to lymphocyte ratio (PLR) and neutrophil to lymphocyte ratio (NLR) in patients with pulmonary hypertension[J]. Tanaffos, 2022, 21(4): 480-486.
    [20]
    TIAN B W, YANG Y F, YANG C C, et al. Systemic immune-inflammation index predicts prognosis of cancer immunotherapy: systemic review and meta-analysis[J]. Immunotherapy, 2022, 14(18): 1481-1496. doi: 10.2217/imt-2022-0133
    [21]
    ZUO H H, XIE X C, PENG J H, et al. Predictive value of novel inflammation-based biomarkers for pulmonary hypertension in the acute exacerbation of chronic obstructive pulmonary disease[J]. Anal Cell Pathol (Amst), 2019: 5189165. DOI: 10.1155/2019/5189165.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(6)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (67) PDF downloads(9) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return